| Editor’s Note: FierceBiotech will not publish on Monday in observance of Presidents Day, but we’ll be back in your inbox on Tuesday, Feb. 18.
Today's Rundown Featured Story | | | Friday, February 14, 2020 In its fourth-quarter earnings out early Friday morning, U.K.-based Big Pharma AstraZeneca has cut two early-stage experimental meds. |
|
|---|
|
|  | QUALITY. SPEED. VALUE.
You Can Have It All. We have successfully delivered therapeutic-quality antibodies to our partners for even the most challenging projects. We deliver lead candidates in a greater number and in a shorter timeline than other CROs that use transgenic animals, in vitro display or humanization. Our expert team of scientists can do the same for your antibody discovery project. Contact us at info@alivamab.com to learn more alivamab.com |
Top Stories Friday, February 14, 2020 CICC Capital has raised a RMB 1.6 billion ($229 million) biologic investment fund. The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing target. Friday, February 14, 2020 For the last year, biopharma veteran Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate, sacituzumab govitecan. Now, she’s signing on with the company full-time as its new chief medical officer. Itri joins from The Medicines Company, where she oversaw global health sciences and medical affairs. Friday, February 14, 2020 A U.S. bankruptcy court has given groups interested in buying antibiotic biotech Melinta Therapeutics until March 2 to make an offer. The bidding process creates an opportunity for Melinta’s business to continue as a going concern despite its financial difficulties. Friday, February 14, 2020 Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda. Friday, February 14, 2020 Scientists at City of Hope discovered that prediabetic and obese mice that lacked the BMAL1 protein, which is made by a gene involved in circadian rhythms, suffered from accelerated tumor growth in triple-negative breast cancer. They believe the finding could point to new treatment targets, as well as prevention strategies for overweight people. Thursday, February 13, 2020 In this week's EuroBiotech Report, Ipsen takes €669 million hit, Roche Alzheimer's drug fails trial and Chiesi creates rare disease unit. Friday, February 14, 2020 A Chinese drugmaker has started mass producing a generic to Gilead's remdesivir without any licensing agreement. HER2-targeting Enhertu has got off to a fast start, Daiichi Sankyo U.S. chief said. Roche's Tecentriq won approval in China in first-line small cell lung cancer. And more. Friday, February 14, 2020 Vividion nabs ex-Pfizer R&D head Abraham; Lu takes CMO role at Pharvaris; Enterprise taps Morris as medical head. |  | [Survey] Bioavailability Toolkit Share insight on the drug developer’s perspective on bioavailability enhancement technologies and the reasoning behind the use of certain technologies in preclinical and early-stage clinical development. Take survey. |
Resources Sponsored by: Medidata To conduct a successful trial, do you need to understand the global eConsent Regulatory landscape? Sponsored by: USDM Life Sciences Details on the FDA’s upcoming Computer System Validation guidance Sponsored by: Veeva Learn how data management teams at ICON, Bioforum, and Vertex Pharmaceuticals are creating the spec and casebook in a single step, reducing study build times and effort by over 50%. Sponsored by: Quotient Sciences Tufts Center for the Study of Drug Development (CSDD) white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms. Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. | 
